CRS Clinical Research Services

CRS. Commitment. Conviction.    We’re excited to unveil the new CRS brand identity—an evolution that respects our past as we boldly step into the future.   Our new look, with a modern logo, vibrant colors, and striking design, represents more than just a facelift; it reflects our strong commitment to excellence, advancing healthcare, and improving patients' lives.   Join us in this transformation and be part of our journey as we continue with the same dedication, energized by a fresh new vision. Explore the new CRS and see how we’re shaping the future—together. 

As 2024 comes to a close, we want to express our deepest gratitude to everyone who has been part of our journey. A heartfelt thank you to our exceptional partners, clients, and colleagues for your unwavering commitment to advancing clinical research. Your support has been invaluable, and we are excited to continue making a meaningful impact in 2025 and beyond. Wishing you a well-deserved holiday break and a bright new year ahead! #HappyHolidays #CRS

We are proud to share that "Diabetes mellitus und Herz" (Diabetes Mellitus and the Heart), co-authored by our Chief Medical Officer Thomas Forst, Prof. Dr., is available on Thieme online! This article explores critical updates in the management of cardiovascular disease in patients with diabetes. With new guidelines and cutting-edge insights, it’s a must-read for healthcare professionals and researchers working at the intersection of cardiology and diabetes care. Check out the article here: https://lnkd.in/e9yuiH7W #DiabetesCare #Cardiology #ClinicalResearch #CRS

Why CRS? Find out at #JPM2025! Are you attending J.P. Morgan’s Annual Healthcare Conference this January? Don’t miss the chance to learn why CRS is the ideal partner for your drug development journey. Connect with our CEO, Elisabeth Lackner, at #JPMWeek to discover how we can help ensure the success of your clinical trials. 📅 Schedule your meeting with Elisabeth today: https://lnkd.in/eyVmGv4y 🌐 Contact us to learn more: https://lnkd.in/gX85eBEb We look forward to seeing you in San Francisco! #JPM2025 #JPMWeek #CRS

Exciting Leadership Update! Catherine Canales, our Chief Commerical Officer, will be taking on the additional role of Chief Diversity, Equity, and Inclusion Officer at CRS. With her extensive experience in commercial strategy and her dedication to fostering a more inclusive and equitable workplace, Catherine will lead efforts to integrate these principles into every facet of our business—from daily operations to leadership development. This expanded role underscores our commitment to fostering an inclusive culture and ensuring that DEI is central to our growth and long-term success. By embedding DEI into our business strategy, we strengthen talent acquisition, boost employee engagement, and foster innovation through diverse perspectives. These efforts not only build a more inclusive and productive workplace, but also enhance our ability to meet evolving market demands and deliver exceptional service to our clients. We’re eager to see Catherine’s impact as she leads our efforts to foster growth and deepen the culture that drives CRS! #DEI #CRS #InclusiveLeadership

The holidays may be just around the corner, but at CRS, we’re already looking ahead to #JPM2025 in January! Elisabeth Lackner, CEO, will be in San Francisco to discuss how CRS can help accelerate your drug development process. As Europe’s largest early-phase CRO, we bring 47+ years of experience in managing complex clinical trials across diverse therapeutic areas. With access to a robust database of over 37,000 active healthy volunteers and patients, we specialize in delivering efficient, expedited, and compliant trial solutions that are tailored to your unique needs. 📅 Schedule your meeting with Elisabeth today: https://lnkd.in/eyVmGv4y 🌐 Contact us to learn more: https://lnkd.in/gX85eBEb Let’s connect at #JPMWeek and explore how we can drive the success of your clinical trials. We hope to see you there! #JPM2025 #JPMWeek #CRS #EarlyPhase

Another Exciting Addition to the CRS Team: Welcome Dr. Maria Lehretz , Our New Medical Director for CRS Kiel! With extensive experience across various therapeutic areas and a strong track record in clinical trial design, regulatory affairs, and process innovation, Dr. Lehretz is well-positioned to make a significant impact on our Kiel Unit and beyond. Her expertise, coupled with her enthusiasm, will be a key driver as we advance our clinical research initiatives. Please join us in giving Dr. Lehretz a warm welcome to CRS! 🎉

Please join us in welcoming our new Team Lead Human Resources, Kathrin Kandefer-Boscher! With over 20 years of HR leadership experience, Kathrin has a proven track record of building strong, people-centered cultures. We’re excited to have her on board to lead our HR team and drive our mission of empowering talent and strengthening our organizational values. We look forward to the great things Kathrin will accomplish as she takes our HR team to new heights. Let’s all give her a warm welcome to the CRS team! 🙌

What’s the Secret to Driving Innovation in Clinical Research? Our Chief Commercial Officer Catherine Canales spoke with with Alex Purnell of Arena International Events Group at this year's OCT New England to share her thoughts on what’s shaping the future of our industry: AI, technology, and the untapped power of collaboration. Her key insight? Progress happens when we work together—not just with sponsors, but with competitors and service providers, too. These connections inspire fresh ideas and drive partnerships that push clinical research forward. Want to get the most out of events like OCT? Show up with intention. Listen, share, and engage meaningfully to spark real change. Don’t miss her full interview—watch it below! 📽️ https://lnkd.in/eRMFFd4S #OCTNewEngland #CRS #ClinicalResearch

CRS Clinical Research Services where women hold 50% of c-suite positions was represented by CEO Elisabeth Lackner at an influential panel of female board leaders this week, discussing the unique value women bring to supervisory board dynamics. The discussion revealed how female leadership styles are transforming corporate governance through enhanced stakeholder engagement, more thorough risk assessment, and innovative approaches to strategic oversight. The panel shared compelling insights into how women in board positions are reshaping corporate culture. The event demonstrated that when women take their seats at the highest levels of corporate oversight, they bring not just expertise but also fresh approaches to leadership that enhance board effectiveness and corporate performance. CRS Clinical Research Services balanced executive leadership team stands as a testament to the company's commitment to diverse leadership perspectives.